Support for fast-tracking new drugs into clinical trials for childhood acute leukemia
- OPACC
- Sep 9, 2015
- 1 min read
Children's Cancer Institute, under the direction of Principal Investigator, Professor Richard Lock, Head of the Leukaemia Biology Program, has been awarded close to US$2 million for 5 years under the Pediatric Preclinical Testing Consortium (PPTC), created by NCI to prioritise and fast-track new drugs into clinical trials in children with aggressive cancers.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Comments